- Home
- FHN vs TGTX Comparison
FHN vs TGTX Comparison
Compare FHN & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHN
- TGTX
- Stock Information
- Founded
- FHN 1864
- TGTX 1993
- Country
- FHN United States
- TGTX United States
- Employees
- FHN N/A
- TGTX N/A
- Industry
- FHN Major Banks
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- FHN Finance
- TGTX Health Care
- Exchange
- FHN Nasdaq
- TGTX Nasdaq
- Market Cap
- FHN 10.4B
- TGTX 5.4B
- IPO Year
- FHN N/A
- TGTX 1995
- Fundamental
- Price
- FHN $20.05
- TGTX $30.69
- Analyst Decision
- FHN Buy
- TGTX Strong Buy
- Analyst Count
- FHN 14
- TGTX 6
- Target Price
- FHN $20.57
- TGTX $40.67
- AVG Volume (30 Days)
- FHN 6.1M
- TGTX 2.0M
- Earning Date
- FHN 01-16-2025
- TGTX 02-26-2025
- Dividend Yield
- FHN 2.98%
- TGTX N/A
- EPS Growth
- FHN N/A
- TGTX N/A
- EPS
- FHN 1.37
- TGTX N/A
- Revenue
- FHN $3,071,000,000.00
- TGTX $264,790,000.00
- Revenue This Year
- FHN N/A
- TGTX $44.11
- Revenue Next Year
- FHN $2.11
- TGTX $63.92
- P/E Ratio
- FHN $14.71
- TGTX N/A
- Revenue Growth
- FHN 0.03
- TGTX 39.53
- 52 Week Low
- FHN $12.95
- TGTX $12.84
- 52 Week High
- FHN $21.72
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- FHN 53.51
- TGTX 46.32
- Support Level
- FHN $19.91
- TGTX $29.90
- Resistance Level
- FHN $20.34
- TGTX $33.55
- Average True Range (ATR)
- FHN 0.48
- TGTX 1.75
- MACD
- FHN -0.05
- TGTX -0.39
- Stochastic Oscillator
- FHN 72.53
- TGTX 17.45
About FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The regional bank is responsible for roughly 65% of its revenue, while capital markets make a 25% contribution. The remainder is split between the firm's non-strategic (wind-down) and corporate operations. First Horizon concentrates on offering a variety of banking products mainly in its home state, where it has the second- largest deposit franchise with a 13% deposit market share.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.